PH26962A - Process for direct isolation of captopril - Google Patents
Process for direct isolation of captopril Download PDFInfo
- Publication number
- PH26962A PH26962A PH41385A PH41385A PH26962A PH 26962 A PH26962 A PH 26962A PH 41385 A PH41385 A PH 41385A PH 41385 A PH41385 A PH 41385A PH 26962 A PH26962 A PH 26962A
- Authority
- PH
- Philippines
- Prior art keywords
- acidification
- effected
- aqueous solution
- sodium
- lithium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 title abstract description 43
- 229960000830 captopril Drugs 0.000 title abstract description 36
- 238000002955 isolation Methods 0.000 title abstract description 4
- 239000000758 substrate Substances 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 13
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 6
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 6
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 5
- 239000011707 mineral Substances 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 26
- 230000020477 pH reduction Effects 0.000 claims description 19
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 7
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- 239000012298 atmosphere Substances 0.000 claims description 3
- 239000003729 cation exchange resin Substances 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 7
- 229910001416 lithium ion Inorganic materials 0.000 claims 3
- 229910001414 potassium ion Inorganic materials 0.000 claims 3
- 101100167365 Caenorhabditis elegans cha-1 gene Proteins 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 abstract description 12
- 239000012535 impurity Substances 0.000 abstract description 11
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract description 10
- 239000003960 organic solvent Substances 0.000 abstract description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 5
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 abstract description 3
- 239000011701 zinc Substances 0.000 abstract description 2
- 229910052725 zinc Inorganic materials 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 229960000443 hydrochloric acid Drugs 0.000 description 7
- 235000011167 hydrochloric acid Nutrition 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- -1 alkali metal salt Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Chemical group 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940097633 capoten Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000011591 potassium Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- HIZCIEIDIFGZSS-UHFFFAOYSA-L trithiocarbonate Chemical compound [S-]C([S-])=S HIZCIEIDIFGZSS-UHFFFAOYSA-L 0.000 description 1
- 239000012989 trithiocarbonate Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Semiconductor Lasers (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/432,028 US5026873A (en) | 1989-11-06 | 1989-11-06 | Process for direct isolation of captopril |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26962A true PH26962A (en) | 1992-12-28 |
Family
ID=23714462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH41385A PH26962A (en) | 1989-11-06 | 1990-10-16 | Process for direct isolation of captopril |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5026873A (fr) |
| EP (1) | EP0427435B1 (fr) |
| JP (1) | JPH03169856A (fr) |
| KR (1) | KR0163956B1 (fr) |
| CN (1) | CN1028169C (fr) |
| AT (1) | ATE119148T1 (fr) |
| AU (1) | AU635341B2 (fr) |
| CA (1) | CA2027377A1 (fr) |
| CY (1) | CY1852A (fr) |
| CZ (1) | CZ277714B6 (fr) |
| DE (1) | DE69017355T2 (fr) |
| DK (1) | DK0427435T3 (fr) |
| EG (1) | EG18964A (fr) |
| ES (1) | ES2068349T3 (fr) |
| FI (1) | FI98814C (fr) |
| HK (1) | HK109895A (fr) |
| HU (1) | HU208525B (fr) |
| IE (1) | IE67284B1 (fr) |
| IL (1) | IL96018A (fr) |
| MX (1) | MX166721B (fr) |
| MY (1) | MY106445A (fr) |
| NO (1) | NO904796L (fr) |
| NZ (1) | NZ235958A (fr) |
| PH (1) | PH26962A (fr) |
| PL (1) | PL287642A1 (fr) |
| PT (1) | PT95781B (fr) |
| RU (1) | RU2001909C1 (fr) |
| SK (1) | SK278604B6 (fr) |
| ZA (1) | ZA908523B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU208954B (en) * | 1990-09-21 | 1994-02-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing 1-(3-mercapto-(2s)-methyl-1-oxo-propyl)-l-prolyn |
| US5387697A (en) * | 1994-06-13 | 1995-02-07 | Merck & Co., Inc. | Process for the preparation of 1-[3-acetylthio-2(s)-methylpropanoyl]-l-proline |
| JP3980684B2 (ja) * | 1996-10-11 | 2007-09-26 | 株式会社カネカ | 高品質カプトプリルの簡便な製造方法 |
| CN107652215A (zh) * | 2017-09-19 | 2018-02-02 | 重庆西南制药二厂有限责任公司 | 一种卡托普利的制备方法 |
| CN110146624B (zh) * | 2019-06-14 | 2022-02-22 | 湖南汉森制药股份有限公司 | 一种卡托普利有关物质的检测方法 |
| CN110950792A (zh) * | 2019-12-11 | 2020-04-03 | 华中药业股份有限公司 | 一种卡托普利的改进制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4105776A (en) * | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
| AU509899B2 (en) * | 1976-02-13 | 1980-05-29 | E.R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
| US4241076A (en) * | 1978-02-21 | 1980-12-23 | E. R. Squibb & Sons, Inc. | Halogenated substituted mercaptoacylamino acids |
| NL7809120A (nl) * | 1978-09-07 | 1980-03-11 | Oce Andeno B V Grubbenvorsterw | Werkwijze voor de bereiding van proline-derivaten. |
| US4297282A (en) * | 1979-03-02 | 1981-10-27 | Sumitomo Chemical Company, Limited | Resolution of mercaptopropionic acids |
| HU184082B (en) * | 1979-12-29 | 1984-06-28 | Egyt Gyogyszervegyeszeti Gyar | Process for preparing 1-3-/3mercapto-/2s/-methyl-propinyl/-pyrrolidine-/2s/-carboxylic acid |
| US4332726A (en) * | 1980-08-25 | 1982-06-01 | E. R. Squibb & Sons, Inc. | Purification of mercaptoacyl amino acids |
| JPS58124764A (ja) * | 1982-01-20 | 1983-07-25 | Kanegafuchi Chem Ind Co Ltd | 光学活性チオ−ル化合物の製造法 |
| KR870001570B1 (ko) * | 1984-12-19 | 1987-09-04 | 보령제약 주식회사 | 피롤리딘 유도체의 제조방법 |
| IL91581A (en) * | 1988-09-13 | 1993-07-08 | Sepracor Inc | Methods for preparing optically active captopril and its analogues |
-
1989
- 1989-11-06 US US07/432,028 patent/US5026873A/en not_active Expired - Lifetime
-
1990
- 1990-10-10 AU AU63977/90A patent/AU635341B2/en not_active Ceased
- 1990-10-11 CA CA002027377A patent/CA2027377A1/fr not_active Abandoned
- 1990-10-11 MY MYPI90001775A patent/MY106445A/en unknown
- 1990-10-16 PH PH41385A patent/PH26962A/en unknown
- 1990-10-16 IL IL9601890A patent/IL96018A/en not_active IP Right Cessation
- 1990-10-19 IE IE375990A patent/IE67284B1/en not_active IP Right Cessation
- 1990-10-24 ZA ZA908523A patent/ZA908523B/xx unknown
- 1990-10-29 DK DK90311824.8T patent/DK0427435T3/da active
- 1990-10-29 ES ES90311824T patent/ES2068349T3/es not_active Expired - Lifetime
- 1990-10-29 EP EP90311824A patent/EP0427435B1/fr not_active Expired - Lifetime
- 1990-10-29 AT AT90311824T patent/ATE119148T1/de not_active IP Right Cessation
- 1990-10-29 DE DE69017355T patent/DE69017355T2/de not_active Expired - Fee Related
- 1990-10-31 MX MX023131A patent/MX166721B/es unknown
- 1990-11-02 CZ CS905405A patent/CZ277714B6/cs not_active IP Right Cessation
- 1990-11-02 SK SK5405-90A patent/SK278604B6/sk not_active IP Right Cessation
- 1990-11-04 EG EG600690A patent/EG18964A/xx active
- 1990-11-05 KR KR1019900017821A patent/KR0163956B1/ko not_active IP Right Cessation
- 1990-11-05 PT PT95781A patent/PT95781B/pt not_active IP Right Cessation
- 1990-11-05 RU SU904831477A patent/RU2001909C1/ru not_active IP Right Cessation
- 1990-11-05 NZ NZ235958A patent/NZ235958A/xx unknown
- 1990-11-05 HU HU907031A patent/HU208525B/hu not_active IP Right Cessation
- 1990-11-05 NO NO90904796A patent/NO904796L/no unknown
- 1990-11-05 FI FI905467A patent/FI98814C/fi active IP Right Grant
- 1990-11-06 CN CN90108901A patent/CN1028169C/zh not_active Expired - Fee Related
- 1990-11-06 PL PL28764290A patent/PL287642A1/xx unknown
- 1990-11-06 JP JP2302311A patent/JPH03169856A/ja active Pending
-
1995
- 1995-07-06 HK HK109895A patent/HK109895A/xx not_active IP Right Cessation
-
1996
- 1996-03-08 CY CY185296A patent/CY1852A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5026873A (en) | Process for direct isolation of captopril | |
| US20100087638A1 (en) | Process for the preparation of lamotrigine | |
| EP0970947B1 (fr) | Procede de production de derives d'ester butyrique | |
| US4346045A (en) | Process for resolving DL-S-benzoyl-β-mercaptoisobutyric acid, and products obtained | |
| KR20110013420A (ko) | 2,4,6-트리머캅토-ｓ-트리아진의 3나트륨 염을 제조하는 방법 | |
| US5304677A (en) | Method for producing 2,6-dihydroxybenzoic acid | |
| US6572834B2 (en) | Aqueous zinc nitrite solution and method for preparing the same | |
| US4418016A (en) | Method for recovering omega-amino-dodecanoic acid from crystallization mother liquors | |
| US5856563A (en) | Process and producing taurine analogues | |
| US4670561A (en) | Process for obtaining hydrochloric salts of 2, 5, 6-triamino-4 (1h)-pyrimidinone | |
| US4889929A (en) | Preparation of 1'-ethoxycarbonyl-oxyethyl esters of penicillins | |
| JP3316917B2 (ja) | 新規フェニルアラニン塩結晶とその製造法 | |
| JPH08157444A (ja) | アミノエタンスルホン酸の製造方法 | |
| JP3167516B2 (ja) | タウリン精製に使用したアルコールの回収方法 | |
| KR800001550B1 (ko) | 5-(4-히드록시페닐) 히단토인의 제조법 | |
| JPH05140087A (ja) | システアミンの精製方法 | |
| JPH04169558A (ja) | 光学活性１，２―プロパンジアミンの製造方法 | |
| JPH04260607A (ja) | トリチオ炭酸塩類の製造法 | |
| US20030013903A1 (en) | Process for crystallization of 2-acetylthio-3-phenyl-propionic acid | |
| JPH03223236A (ja) | 光学活性１，２―プロパンジアミンの製造法 | |
| JPH06247937A (ja) | ２−ブチル−４−フォルミルイミダゾールの合成方法 | |
| JPH0372446A (ja) | 光学活性１，２―プロパンジアミンの製法 | |
| JPS6051165A (ja) | シスタミン硫酸塩類の製造法 | |
| JPH02152970A (ja) | ウラシルの製造方法 |